Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck
Public ClinicalTrials.gov record NCT02319044. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination With Tremelimumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the efficacy and safety of investigational medical products (MEDI4736 monotherapy, tremelimumab monotherapy, and MEDI4736 + tremelimumab combination therapy) in the treatment of patients with recurrent or metastatic carcinoma of the head and neck who have progressed during or after treatment with a platinum containing regimen for recurrent/metastatic disease.
Study identification
- NCT ID
- NCT02319044
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 267 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 96 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 15, 2015 (Actual)
- Primary completion
- Sep 26, 2016 (Actual)
- Completion
- Jul 6, 2020 (Actual)
- Last update posted
- Sep 29, 2020
2015 – 2020
United States locations
- U.S. sites
- 43
- U.S. states
- 24
- U.S. cities
- 41
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | 35294 | — |
| Research Site | Yuma | Arizona | 85364 | — |
| Research Site | Little Rock | Arkansas | 72205 | — |
| Research Site | Downey | California | 90241 | — |
| Research Site | Duarte | California | 91010-3012 | — |
| Research Site | La Jolla | California | 92093 | — |
| Research Site | Long Beach | California | 90813 | — |
| Research Site | Los Angeles | California | 90033 | — |
| Research Site | Los Angeles | California | 90095 | — |
| Research Site | San Francisco | California | 94115 | — |
| Research Site | Aurora | Colorado | 80045 | — |
| Research Site | Tampa | Florida | 33612 | — |
| Research Site | Atlanta | Georgia | 30322 | — |
| Research Site | Augusta | Georgia | 30912 | — |
| Research Site | Macon | Georgia | 31201 | — |
| Research Site | Chicago | Illinois | 60637 | — |
| Research Site | Evanston | Illinois | 60201 | — |
| Research Site | Lexington | Kentucky | 40536-0001 | — |
| Research Site | Baltimore | Maryland | 21201 | — |
| Research Site | Baltimore | Maryland | 21204 | — |
| Research Site | Boston | Massachusetts | 02215 | — |
| Research Site | Ann Arbor | Michigan | 48109 | — |
| Research Site | Detroit | Michigan | 48201 | — |
| Research Site | Southfield | Michigan | 48075 | — |
| Research Site | Rochester | Minnesota | 55905-0001 | — |
| Research Site | St Louis | Missouri | 63110 | — |
| Research Site | Lebanon | New Hampshire | 03756 | — |
| Research Site | New York | New York | 10032 | — |
| Research Site | Stony Brook | New York | 11794 | — |
| Research Site | The Bronx | New York | 10467 | — |
| Research Site | Durham | North Carolina | 27705 | — |
| Research Site | Winston-Salem | North Carolina | 27157 | — |
| Research Site | Portland | Oregon | 97239 | — |
| Research Site | Bethlehem | Pennsylvania | 18015 | — |
| Research Site | Pittsburgh | Pennsylvania | 15232 | — |
| Research Site | Charleston | South Carolina | 29425 | — |
| Research Site | Knoxville | Tennessee | 37909 | — |
| Research Site | Nashville | Tennessee | 37232 | — |
| Research Site | Arlington | Texas | 76012 | — |
| Research Site | Austin | Texas | 78701 | — |
| Research Site | Dallas | Texas | 75230 | — |
| Research Site | Morgantown | West Virginia | 26506 | — |
| Research Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 82 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02319044, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 29, 2020 · Synced Nov 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02319044 live on ClinicalTrials.gov.